Descripción del proyecto
Nuevos biofármacos dirigidos al sistema nervioso central
Millones de ciudadanos europeos sufren trastornos del sistema nervioso central (SNC) como la esclerosis múltiple, la enfermedad de Alzheimer y la enfermedad de Parkinson. En la actualidad, los medicamentos con baja biodisponibilidad en el SNC se suministran directamente al SNC mediante inyecciones intratecales, intracerebroventriculares o intraparenquimatosas que, sin embargo, requieren cirugía. Para hacer frente a esta limitación, en el proyecto financiado con fondos europeos Bio2Brain se formará a investigadores noveles para desarrollar tecnologías innovadoras para la administración de biofármacos por vía nasal de forma segura. Se espera que los resultados del proyecto aborden la escasa disponibilidad de medicamentos dirigidos al SNC, incluidos biofármacos como los anticuerpos monoclonales, que sigue siendo un importante problema para el tratamiento de los trastornos del SNC.
Objetivo
Bio2Brain aims to create a trans-European network of industrially oriented specialists fully trained and experienced, a significant driving force in innovating novel technologies to deliver biopharmaceuticals safely and via the nasal route of administration to the central nervous system (CNS). Diseases of the CNS and the spinal cord affect around 165 million Europeans with disorders such as Multiple Sclerosis, Alzheimer’s disease and Parkinson’s disease. CNS disorders are often connected with high morbidity, significant side effects, suffering of the patients and their families, as well as an enormous burden on the welfare systems. Therefore, in terms of social sustainability, Bio2Brain contributes to increased benefit for both, the society as whole and particularly for those individuals at a disadvantage through these disorders. A highly critical challenge of CNS diseases is the low central availability drugs in general and in particular of biopharmaceuticals like monoclonal antibodies (mAbs). Hence, approved medicinal products with a low CNS bioavailability are currently delivered via intrathecal, intracerebroventricular or intraparenchymal injections. In this way, they are delivered directly to the CNS. Unfortunately, such delivery systems are invasive, require a surgery with high risks, have a low patient compliance and are poorly controllable. Therefore, there is a critical need for a more safe and effective new approach, that means a paradigm shift, for drug delivery technologies in the treatment of CNS diseases. The Bio2Brain network will create a research environment for the interdisciplinary and intersectorial training of 13 ESRs supported by 11 academic teams (beneficiaries and partner universities), 6 key industrial stakeholders and an academic non-profit organization. As an important benefit, the close and frequent exposure of the ESRs to the private sector and to key technologies will significantly enhance their employability.
Ámbito científico
Palabras clave
Programa(s)
Régimen de financiación
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinador
80686 Munchen
Alemania